About Libradoma(TM)
The Libradoma(TM) technology process utilizes Human MORPHODOMA(R) and other propriety technologies to generate libraries potentially comprised of thousands of hybridomas that can be rapidly screened using high-throughput robotics to identify hybridomas expressing human antibodies with target affinity profiles.
For further media information in Europe, please contact: Andrew Day, Eisai Europe Ltd, +44-(0)208-600-1400 Andrew_Day@eisai.net or Eisai Contact Information, Corporate Communications Department, Eisai Co., Ltd., +81-3-3817-5120, webmaster@eisai.co.jp, ECA Contact Information, Cathy Pollini, Corporate Planning and Communications, Eisai Inc., +1-201-746-2052, cathy_pollini@eisai.com, Morphotek Contact Information, Nicholas Nicolaides, President & CEO, Morphotek Inc., +1-610-423-6100, nicolaides@morphotek.com